ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic—a randomized controlled trial
Study context
- Population
- Patients with T2D and CVD, Cardiovascular Research Unit, Odense University Hospital Svendborg, Denmarkplanned
- Participants
- 1,500 patients
- Planned comparison
- Treatment in a Cardio-Metabolic Clinic vs standard of care
- Primary endpoint
- Time to first occurrence of composite of:
- Cardiovascular death
- Non-fatal acute MI
- Non-fatal stroke
- Hospitalization for HF
- Follow-up
- Five years
Methodological detailsprotocol, prospective, randomized 2:1, Health examinations at baseline and after three years; clinical events assessed through registry and journal audits after five and ten years
- Protocol
- Prospective
- Randomized 2:1
- Health examinations at baseline and after three years; clinical events assessed through registry and journal audits after five and ten years
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
ProtecT-2-D trial protocol: cardiovascular protection in patients with type 2 diabetes and established heart and/or vascular disease at a cardio-metabolic clinic—a randomized controlled trial. Cardiovasc Diabetol. Published 8 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →